Describe The Mechanism of Action of Ixekizumab

Christy Vath, PA-C, from Seattle Rheumatology in Washington, provides a concise yet insightful overview of the mechanism of action of Ixekizumab, a targeted IL-17A inhibitor designed for the treatment of autoimmune diseases, including psoriasis (PSO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA).

Ixekizumab is a humanized monoclonal antibody that selectively targets IL-17A, a key pro-inflammatory cytokine involved in the pathogenesis of psoriatic and spondyloarthritic conditions. By inhibiting IL-17A, Ixekizumab helps to reduce inflammation, prevent tissue damage, and alleviate symptoms associated with these chronic conditions. The discussion also covers the role of IL-17A inhibition in both radiographic and non-radiographic axSpA, highlighting its impact on disease progression and patient outcomes.

This session is essential for rheumatology APPs, clinicians, and healthcare providers seeking to stay updated on the latest targeted therapies in autoimmune disease management.

For more expert insights and the latest advancements in rheumatology, download the RhAPP ACE App for valuable resources and clinical updates.